RESUMEN
INTRODUCTION: Enhancement of mucociliary clearance (MCC) might be a potential target in treating COVID-19. The phytomedicine ELOM-080 is an MCC enhancer that is used to treat inflammatory respiratory diseases. PATIENTS/METHODS: This randomised, double-blind exploratory study (EudraCT number 2020-003779-17) evaluated 14 days' add-on therapy with ELOM-080 versus placebo in patients with COVID-19 hospitalised with acute respiratory insufficiency. RESULTS: The trial was terminated early after enrolment of 47 patients as a result of poor recruitment. Twelve patients discontinued prematurely, leaving 35 in the per-protocol set (PPS). Treatment with ELOM-080 had no significant effect on overall clinical status versus placebo (p = 0.49). However, compared with the placebo group, patients treated with ELOM-080 had less dyspnoea in the second week of hospitalisation (p = 0.0035), required less supplemental oxygen (p = 0.0229), and were more often without dyspnoea when climbing stairs at home (p < 0.0001). CONCLUSION: These exploratory data suggest the potential for ELOM-080 to improve respiratory status during and after hospitalisation in patients with COVID-19.
Asunto(s)
COVID-19 , Insuficiencia Respiratoria , COVID-19/complicaciones , Método Doble Ciego , Disnea/tratamiento farmacológico , Disnea/etiología , Humanos , Estudios Prospectivos , Insuficiencia Respiratoria/tratamiento farmacológico , SARS-CoV-2 , Resultado del TratamientoRESUMEN
BACKGROUND: As with other inflammatory diseases, the (dry) cough in COVID-19 patients indicates that mucociliary clearance (MCC) is at least at risk, if not overloaded, damaged or largely inoperable. Coughing is an important secondary mechanism that only takes over bronchial cleansing as a replacement if the MCC has failed. METHOD: The review article describes the physiology and pathophysiology of MCC and its possible role in the pathogenesis of COVID-19. RESULTS AND CONCLUSIONS: Human and animal studies as well as autopsy reports indicate that MCC could also be important for the COVID-19 pathogenesis. In primary care, MCC plays a major role in inflammatory respiratory diseases. In Germany, drugs for self-medication are approved for treatment and, due to the high quality of studies, are also recommended in the respective guidelines. A symptomatic approach to stabilize the airway barrier would also be conceivable in the early outpatient phase of COVID-19.